If you’ve tried antidepressant after antidepressant and still don’t feel like yourself, you’ve probably heard about Spravato® and wondered if it’s actually within reach financially. It’s a fair question. Spravato® (esketamine) is a prescription nasal spray, but it’s not something you pick up at a pharmacy counter and pay a $10 copay for. It’s administered in a clinical setting, under supervision, which naturally raises the question: is Spravato® covered by insurance in Reading, PA?
The short answer is yes — most major insurance plans, including Medicare and many Medicaid plans, cover Spravato® for people who qualify. But “covered” doesn’t always mean “free,” and the process of getting approved involves some specific steps. Below, we’ll walk through exactly how coverage works, what it typically costs out of pocket, and how to find Spravato therapy in Reading, PA and Berks County if you or a loved one are dealing with depression that hasn’t responded to standard treatment.
What Is Spravato® (Esketamine), Exactly?
Spravato® is the brand name for esketamine, a nasal spray related to the anesthetic ketamine. It works differently than traditional antidepressants like SSRIs or SNRIs. Instead of slowly adjusting serotonin levels over weeks, esketamine acts on the brain’s glutamate system, which appears to help form new neural connections relatively quickly. That’s part of why some patients notice improvement within days or weeks rather than the six-to-eight-week wait typical of standard antidepressants.
The FDA approved Spravato® for two specific situations:
- Treatment-resistant depression (TRD) in adults who have not improved after trying at least two different oral antidepressants at adequate doses and duration
- Major depressive disorder with suicidal thoughts or behavior, used alongside an oral antidepressant
Spravato® is not a medication you take at home. Because of the risk of sedation and a temporary dissociative feeling (a sense of detachment from your surroundings), it’s classified as a Schedule III controlled substance and must be given under a Risk Evaluation and Mitigation Strategy, or REMS, established by the FDA. In practice, that means you use the nasal spray in a certified doctor’s office or clinic, and a member of the care team monitors you for at least two hours afterward to make sure you’re safe to leave.
This is also the reason insurance handles Spravato® differently than a typical prescription. Because it can’t be picked up at a pharmacy and taken home, it’s billed as a medical service, not a retail drug.
Is Spravato® Covered by Insurance? The Short Answer
Yes. Most commercial insurance plans, Medicare, and many state Medicaid programs — including Pennsylvania Medicaid — provide coverage for Spravato® when a patient meets the clinical criteria for treatment-resistant depression. That said, coverage almost always comes with conditions attached:
- Prior authorization from your insurance company
- Documentation that you’ve tried and not responded to at least two antidepressants from different drug classes
- Treatment delivered at a REMS-certified clinic
- Ongoing monitoring and periodic reauthorization as treatment continues
Let’s break down what this looks like plan by plan.
Medicare Coverage for Spravato®
If you’re on Original Medicare, Spravato® is typically covered under Medicare Part B, not Part D, because it’s administered in a clinical setting rather than dispensed for home use. Part B generally covers a significant portion of the approved treatment cost once you’ve met your annual deductible, with the patient responsible for the remaining coinsurance — usually around 20% — unless you have a Medigap supplemental plan that covers that gap.
If you have a Medicare Advantage plan instead of Original Medicare, coverage details can vary. Some plans use a flat copay per visit rather than a percentage-based coinsurance, and some may require you to use in-network clinics. It’s worth calling the number on your insurance card and asking specifically about coverage for esketamine (Spravato®) for treatment-resistant depression, since customer service reps are used to fielding this exact question.
Medicaid and Spravato®
Medicaid coverage for Spravato® varies significantly from state to state, but Pennsylvania has generally been more favorable than many other states. Pennsylvania Medicaid managed care organizations have covered esketamine therapy with prior authorization when a patient meets the clinical criteria for treatment-resistant depression. If you’re on a Medicaid managed care plan through Pennsylvania, the prior authorization process usually requires your psychiatrist to submit documentation of your prior medication trials and current symptom severity.
Because Medicaid rules and formularies are updated periodically, it’s always worth confirming current details directly with your plan or with the treatment clinic’s billing staff before starting therapy.
Private and Commercial Insurance
Major commercial insurers — including Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare — generally cover Spravato® for patients who meet FDA-labeled criteria for treatment-resistant depression. Nearly all of them require:
- Prior authorization — your prescriber submits paperwork showing medical necessity
- Step therapy documentation — proof that you’ve already tried at least two antidepressants without adequate improvement
- Treatment at an in-network, REMS-certified provider
Once approved, most commercial plans cover Spravato® similarly to other specialty medical treatments, with a copay or coinsurance that depends on your specific plan design.
What Does Spravato® Cost Out of Pocket in Reading, PA?
Even with insurance, it helps to know what to expect financially. A single Spravato® session (which includes the medication, administration, and the required two-hour observation period) is billed as a medical visit rather than a pharmacy transaction. Costs vary by clinic and by how your specific insurance plan structures cost-sharing, so the most accurate number will always come from your insurance provider and the treatment clinic itself.
Here’s the treatment timeline that most insurers use to determine medical necessity and length of coverage:
- Induction phase: Typically twice weekly for the first four weeks
- Maintenance phase: Often reduced to once weekly, then tapered to every one to two weeks based on your response
Because induction requires more frequent visits, the first month tends to carry the highest out-of-pocket costs relative to later maintenance months, especially if you’re paying coinsurance rather than a flat copay.
If cost is a concern, ask your treatment provider about:
- Manufacturer savings programs
- Payment plans
- Whether your plan has a lower-cost, in-network clinic option
Who Qualifies for Spravato®?
Spravato® isn’t the first option most psychiatrists reach for — it’s typically considered after other treatments haven’t worked well enough. Insurance companies use similar criteria to decide whether to approve coverage. Generally, a good candidate:
- Has a diagnosis of major depressive disorder
- Has tried at least two antidepressants from different classes at adequate doses without sufficient improvement (treatment-resistant depression), or has depression with active suicidal thoughts
- Does not have specific medical contraindications, such as certain cardiovascular conditions or a history of substance misuse involving ketamine-like substances
- Is able to attend in-office visits for administration and the required observation period
A thorough psychiatric evaluation is the starting point for determining whether Spravato® — or another option like TMS therapy — is the right next step.
Spravato® vs. TMS Therapy: How Do They Compare?
Patients in Reading often ask whether Spravato® or TMS therapy makes more sense for their situation. Both are FDA-cleared options for depression that hasn’t responded to standard treatment, but they work differently.
Transcranial Magnetic Stimulation (TMS), sometimes called Deep TMS, uses magnetic pulses to stimulate specific areas of the brain associated with mood regulation. It’s non-invasive, doesn’t require sedation, and patients can drive themselves home immediately afterward. Treatment is typically done daily on weekdays over several weeks.
Spravato® works faster for some patients and is often considered when depression includes suicidal thinking, since it has FDA approval specifically for that presentation. It requires in-office administration and a supervised observation period each session, and patients cannot drive themselves home the same day.
Neither option is universally “better” — the right choice depends on your medical history, your symptoms, your schedule, and what your psychiatrist recommends after a full evaluation. Many patients considering either option benefit from a conversation with a psychiatrist who offers both, so the treatment plan is based on your specific needs rather than what one particular clinic happens to offer.
Common Misconceptions About Spravato® and Insurance
“Spravato® is a controlled substance, so insurance won’t touch it.” Not true. Being a Schedule III controlled substance affects how it’s prescribed and monitored, not whether insurance companies will cover it. Coverage is based on FDA-approved indications and medical necessity, not the drug’s scheduling status.
“If I have Medicaid, I automatically won’t get approved.” Pennsylvania Medicaid has covered Spravato® for eligible patients, though the prior authorization process takes some documentation. It’s worth applying rather than assuming denial.
“I need to fail five medications before insurance will approve it.” Most plans require documentation of at least two prior antidepressant trials from different classes, not five. Requirements can vary by plan, so it’s worth confirming specifics with your insurer.
“It’s basically the same as ketamine infusion therapy, so my insurance treats it the same.” Insurance companies treat FDA-approved Spravato® very differently from off-label IV or IM ketamine infusions used for depression. Many plans that cover Spravato® do not cover ketamine infusions for mental health conditions, since ketamine infusions are used off-label for this purpose. This distinction matters a lot when you’re comparing costs and coverage between providers.
When to Talk to a Psychiatrist About Spravato®
If you’ve been on one or more antidepressants for an adequate period and you’re still struggling — persistent low mood, loss of interest in things you used to enjoy, trouble functioning at work or home, or thoughts of suicide or self-harm — it’s time to have a conversation with a psychiatrist about next steps. You don’t need to wait until you’ve exhausted every possible medication combination on your own. A psychiatric evaluation can help determine whether Spravato®, TMS, medication management, or a combination of approaches is the most appropriate path forward.
If you are currently having thoughts of suicide or self-harm, please don’t wait for an appointment — contact the 988 Suicide & Crisis Lifeline by calling or texting 988, or go to your nearest emergency room.
Spravato® Therapy in Reading, PA and Berks County
Options Psychiatry provides Spravato® therapy in Reading, PA, offering esketamine treatment for adults with treatment-resistant depression or major depressive disorder with suicidal ideation. Our team works directly with patients to verify insurance benefits, submit prior authorization paperwork, and walk through what coverage looks like for your specific plan — whether that’s Medicare, Pennsylvania Medicaid, or a private commercial plan.
For residents of Reading, Berks County, and the surrounding Pennsylvania communities, Options Psychiatry also offers TMS therapy in Reading, PA, psychiatric evaluations, medication management, and treatment for depression, anxiety, and OCD, so patients have more than one evidence-based option to consider when standard treatment hasn’t been enough.
Ready to Find Out If Spravato® Is Right for You?
If depression has been running your life despite trying medication after medication, it’s worth finding out what your options actually are — including what your insurance will cover. Options Psychiatry is known throughout Berks County for offering comprehensive, evidence-based psychiatric care, including TMS therapy in Reading, Spravato® therapy in Reading, PA, and OCD treatment in Reading, PA, all under one roof with psychiatrists who take the time to explain your options clearly.
Schedule an appointment with our team today, and we’ll help you understand your insurance coverage, walk you through the Spravato® process step by step, and build a treatment plan suited to your specific situation. When people search for the best psychiatrist in Pennsylvania for treatment-resistant depression, our goal is to be the practice that actually listens and delivers results.
Frequently Asked Questions
1. Is Spravato® covered by insurance?
Yes, most major insurance plans — including Medicare, many Medicaid plans, and commercial insurers — cover Spravato® for patients who meet the FDA criteria for treatment-resistant depression or depression with suicidal ideation, typically after prior authorization.
2. Does Medicare cover Spravato®?
Yes. Medicare typically covers Spravato® under Part B since it’s administered in a clinical setting, with the patient generally responsible for a percentage of the cost as coinsurance unless they have supplemental coverage.
3. Does Medicaid cover Spravato® in Pennsylvania?
Pennsylvania Medicaid has covered Spravato® for eligible patients through managed care plans, generally requiring prior authorization and documentation of treatment-resistant depression.
4. How much does Spravato® cost without insurance?
Costs vary by clinic and location since it’s billed as a medical procedure rather than a flat prescription price. Contact the treatment clinic directly for current self-pay pricing.
5. How many antidepressants do I need to try before insurance covers Spravato®?
Most plans require documentation of at least two antidepressant trials from different classes at adequate doses without sufficient improvement, though exact requirements vary by insurer.
6. Is Spravato® the same as ketamine?
Spravato® (esketamine) is derived from ketamine but is a distinct, FDA-approved formulation specifically studied and approved for depression. It’s not the same as off-label IV ketamine infusions.
7. How long does Spravato® treatment take to work?
Some patients notice improvement within one to two weeks, though individual response varies. Your psychiatrist will monitor your progress during the induction phase.